Simpson Thacher is representing Blackstone in connection with its sale of Alinamin Pharmaceutical Co., Ltd. (“Alinamin”) to MBK Partners. Blackstone will re-invest a minority stake in Alinamin upon closing of the sale. Terms of the transaction were not otherwise disclosed.
Alinamin is a leading consumer healthcare company in Japan focusing on supplements and nonprescription drugs. The Firm also represented Blackstone on its acquisition of Alinamin in 2021 from Takeda Pharmaceutical.
The Simpson Thacher team includes Anthony King, Sonya Ho, Paul Kim and Tiffany Shih (M&A); Étienne Renaudeau, Sarah Chaudhuri and Luke Cowdell (Antitrust); Makiko Harunari and Chenyu Cui (Banking & Credit); Meredith Jones and Paul Jansch (Tax); Ron Ben-Yehuda (Intellectual Property); Steven Klar and Richard Zhang (Funds); and Gregory Grogan and Pasco Struhs (ECEB).